Skip to main
AXSM

Axsome Therapeutics (AXSM) Stock Forecast & Price Target

Axsome Therapeutics (AXSM) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 53%
Buy 41%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

Axsome Therapeutics Inc reported strong third-quarter revenues of $136.1 million, surpassing consensus estimates and demonstrating a robust year-over-year growth of 69% and a quarter-over-quarter increase of 14%. The improvement in payer coverage to 85% and a significant advance in commercial coverage to 75% following a new third-party contracting agreement indicate a favorable regulatory environment, supporting further sales growth. With projected revenue growth outpacing operating costs, the company anticipates becoming cash flow positive in 2026, driven by its innovative product pipeline and solid management strategies.

Bears say

Axsome Therapeutics Inc. experienced a setback as its Phase 3 PARADIGM study for major depressive disorder (MDD) failed to meet overall efficacy endpoints, despite showing statistically significant results in a prespecified subset of patients with excessive daytime sleepiness (EDS). This failure raises concerns about the company's ability to differentiate its treatments in a competitive market, as the differentiation relies heavily on the impact demonstrated in the roughly 50% of the MDD population that experiences EDS. Furthermore, the need to initiate a new Phase 3 study in this specific subset of MDD patients poses additional financial uncertainties and potential delays in bringing its therapies to market.

Axsome Therapeutics (AXSM) has been analyzed by 17 analysts, with a consensus rating of Buy. 53% of analysts recommend a Strong Buy, 41% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Axsome Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Axsome Therapeutics (AXSM) Forecast

Analysts have given Axsome Therapeutics (AXSM) a Buy based on their latest research and market trends.

According to 17 analysts, Axsome Therapeutics (AXSM) has a Buy consensus rating as of Jan 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $186.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $186.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Axsome Therapeutics (AXSM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.